Contrasting Oncology Institute (NASDAQ:TOI) and Sera Prognostics (NASDAQ:SERA)

Sera Prognostics (NASDAQ:SERA) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Institutional & Insider Ownership

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 13.5% of Sera Prognostics shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sera Prognostics and Oncology Institute”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	974.65	-$32.90 million	($0.77)	-2.62
Oncology Institute	$393.41 million	0.71	-$64.66 million	($0.64)	-4.45

Sera Prognostics has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sera Prognostics and Oncology Institute, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	0	1	2.50
Oncology Institute	1	0	3	1	2.80

Sera Prognostics currently has a consensus target price of $5.00, suggesting a potential upside of 147.52%. Oncology Institute has a consensus target price of $6.50, suggesting a potential upside of 128.07%. Given Sera Prognostics’ higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Oncology Institute.

Volatility & Risk

Sera Prognostics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500.

Profitability

This table compares Sera Prognostics and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-34,343.16%	-41.69%	-31.77%
Oncology Institute	-13.21%	-1,527.21%	-35.30%

Summary

Sera Prognostics beats Oncology Institute on 9 of the 14 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.